LSL60101

Selective, orally available I₂-imidazoline receptor ligand (K_i ratio = 286 for α₂ / I₂ receptors). Induces morphological/biochemical changes to astroglia, reduces apoptosis and modulates oxidative stress to show neuroprotective effects. Chronic low-dose treatment of LSL60101 also reverses cognitive deficits and impaired social behaviour in 5XFAD mice to alter Alzheimer's disease markers such as glial activation and synaptic dysfunction. Both LSL60101 treatment and LSL60101 / donepezil combination treatment decreases amyloid-β₄₀ and amyloid-β₄₂ levels, amyloid-β plaque number and tau hyperphosphorylation to attenuate amyloid-β pathology in 5XFAD brains.